HIV vax researchers ponder best R&D strategies

Emboldened by a glimpse of the potential of a new HIV vaccine, more than 1,000 researchers from around the world are gathering in Atlanta this week to share their thoughts on the best strategies for finally finding a shot which can guard against the lethal virus. "Over the past year, scientists have identified neutralizing antibodies against HIV, which are a fundamental building block for developing a vaccine," Mitchell Warren, executive director of the Aids Vaccine Advocacy Coalition, tells the Guardian. Story

Suggested Articles

The under-active genes that cause heart problems and poor muscle movement in Down syndrome may also impede the growth of solid tumors, a study found.

The new funding will bankroll Dyne's preclinical programs in three muscle-wasting diseases, as well as discovery-stage work.

AbbVie and Roche alum Janet Hammond, M.D., Ph.D., Sc.M., F.C.P. has nabbed the chief development officer role at infectious disease biotech Atea.